| Ms Oriana Cruz, NP-C | |
|
2865 Daggett Ave, Klamath Falls, OR 97601-1106 | |
| (541) 274-6175 | |
| (541) 274-6739 |
| Full Name | Ms Oriana Cruz |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 2865 Daggett Ave, Klamath Falls, Oregon |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043794969 | NPI | - | NPPES |
| F08180391 | Other | AANPCB | |
| 0994108-NP | Other | CO | CO BOARD OF NURSING |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | 0024177229 (Virginia) | Secondary |
| 363LF0000X | Nurse Practitioner - Family | 202003147NP-PP (Oregon) | Primary |
| Entity Name | Sky Lakes Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659340370 PECOS PAC ID: 1052204096 Enrollment ID: O20040204000577 |
News Archive
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.
Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
Examination of the placenta can offer answers to the questions that arise following an adverse perinatal outcome, such as stillbirth or intrauterine growth restriction. A placental lesion known as fetal thrombotic vasculopathy (FTV) has been associated with a number of adverse outcomes. By studying placentas with this lesion, researchers hope to determine the risks of such serious complications that affect fetuses and newborns.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Oriana Cruz, NP-C 2865 Daggett Ave, Klamath Falls, OR 97601-1106 Ph: (541) 274-6175 | Ms Oriana Cruz, NP-C 2865 Daggett Ave, Klamath Falls, OR 97601-1106 Ph: (541) 274-6175 |
News Archive
Fenwal, Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal 510(k) clearance to market its Amicus® blood cell separator for collecting human platelets stored in InterSol® platelet additive solution (PAS 3). Fenwal's InterSol® solution was approved by the FDA in December 2009 under a new drug application. It is the first and only platelet additive solution now available in America.
Amgen and UCB (Euronext Brussels:UCB) today announced results from a Phase 2 trial evaluating romosozumab (AMG 785/CDP7851) in postmenopausal women with low bone mineral density (BMD).
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.
Examination of the placenta can offer answers to the questions that arise following an adverse perinatal outcome, such as stillbirth or intrauterine growth restriction. A placental lesion known as fetal thrombotic vasculopathy (FTV) has been associated with a number of adverse outcomes. By studying placentas with this lesion, researchers hope to determine the risks of such serious complications that affect fetuses and newborns.
› Verified 9 days ago
Ms. Barbara G Enos, RN, PMHNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2650 Washburn Way, Suite 180, Klamath Falls, OR 97603 Phone: 541-884-1952 Fax: 541-884-6085 | |
Brady William Sweat, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2865 Daggett Ave, Klamath Falls, OR 97601 Phone: 541-274-6177 Fax: 541-274-6177 | |
Cheri Maureen Monteith, WHCNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2460 Biehn Stree, Suite 1, Klamath Falls, OR 97601 Phone: 541-205-6890 Fax: 541-205-6899 | |
Sara Malzacher, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2821 Daggett Ave Ste 200, Klamath Falls, OR 97601 Phone: 541-274-6221 | |
Eva-lynn Lund, AGPCNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1401 Bryant Williams Dr, Klamath Falls, OR 97601 Phone: 541-810-4765 | |
Sharon K Heaton, F.N.P. Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 3001 Daggett Ave Ste 101, Klamath Falls, OR 97601 Phone: 541-274-3278 Fax: 541-274-3275 |